Opinion|Videos|December 23, 2024
Managing Adverse Events with CAR T-Cell Therapy: Best Practices for Myeloma Care Teams
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Let's start with an overview of the safety profile for CAR-T therapies in multiple myeloma.
- What are the most common and significant adverse events you've observed with ide-cel and cilta-cel?
Advertisement
Related to this article
In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.
In observation of National PA Week, Moffitt PA Mark Honor discusses the expansion of APPs and key collaboration strategies for oncology nurses.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Oncology clinicians gathered to review relapsed CLL care options, CAR T-cell trial updates, and advanced practice provider roles.
At ASTRO 2026, Suresh Rana details how AI-driven contouring accelerates care timelines, requiring rigorous team monitoring and early nursing input.
At ASTRO 2026, Dr. Erica Braschi Jordan details toxicity tracking, physical therapy referral, and quality of life in proton regional nodal irradiation.
At ASTRO 2026, Dr. Mishaal Munir details how nurse-led triage workflows and prompt symptom escalations improve care for breast cancer brain metastases.
ASTRO 2026 presenter Kayla Kafka-Peterson details an Adapt-Adopt-Build model to bridge global brachytherapy nursing gaps and standardize perioperative care.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
On-Body Injectors: What Oncology Nurses and PAs Need to Know
2
Delaying BSO to Age 50 Leaves BRCA1 Carriers With 24% Ovarian Cancer Risk
3
FDA Expands Anktiva Approval to Papillary-Only BCG-Unresponsive NMIBC
4
Anktiva for Papillary NMIBC: What Nurses Need to Know About the Regimen
5